China's indigenous vaccines (Sinovac and Sinopharm) are based on inactivated virus technology. Describing them as "highly effective" is a bit of a stretch: the WHO [1] put the effectiveness at about 50% against symptomatic infection, and a study in Hong Kong [2] concluded that three doses were required to gain a similar level of efficacy to the mRNA vaccines.
The Chinese government has resisted importing Western mRNA vaccines [3], and their own mRNA efforts are not yet up to speed [4].